These promising data that span a range of epithelial malignancies indicate that anti-RSPO antibodies may provide a beneficial treatment for prostate cancer that remains to be explored, particularly in patients with RPSO alterations (up to 21% of cases, Table 1). Here, RSPO1 is linked to Familial prostate cancer.